Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual
daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the
clientele of cardiologists, nephrologists, and diabetologists
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Hydrochlorothiazide Telmisartan Telmisartan, hydrochlorothiazide drug combination